title: The metabolism of clomethiazole in gerbils and the neuroprotective and sedative activity of the metabolites.
abstract: A single dose of clomethiazole (600 micromol kg(-1) i.p.) has previously been shown to be neuroprotective in the gerbil model of global ischaemia. In gerbils, clomethiazole (600 micromol kg(-1)) injection produced a rapid appearance (peak within 5 min) of drug in plasma and brain and similar clearance (plasma t(1/2): 40 min) from both tissues. The peak brain concentration (226+/-56 nmol g(-1)) was 40% higher than plasma. One major metabolite, 5-(1-hydroxyethyl-2-chloro)-4-methylthiazole (NLA-715) and two minor metabolites 5-(1-hydroxyethyl)-4-methylthiazole (NLA-272) and 5-acetyl-4-methylthiazole (NLA-511) were detected in plasma and brain. Evidence suggested that clomethiazole is metabolized directly to both NLA-715 and NLA-272. Injection of NLA-715, NLA-272 or NLA-511 (each at 600 micromol kg(-1)) produced brain concentrations respectively 2.2, 38 and 92 times greater than seen after clomethiazole (600 micromol kg(-1)). Clomethiazole (600 micromol kg(-1)) injected 60 min after a 5 min bilateral carotid artery occlusion in gerbils attenuated the ischaemia-induced degeneration of the hippocampus by approximately 70%. The metabolites were not neuroprotective at this dose. In mice, clomethiazole (600 micromol kg(-1)) produced peak plasma and brain concentrations approximately 100% higher than in gerbils, drug concentrations in several brain regions were similar but 35% higher than plasma. Clomethiazole (ED(50): 180 micromol kg(-1)) and NLA-715 (ED(50): 240 micromol kg(-1)) inhibited spontaneous locomotor activity. The other metabolites were not sedative (ED(50) >600 micromol kg(-1)). These data suggest that the neuroprotective action of clomethiazole results from an action of the parent compound and that NLA-715 contributes to the sedative activity of the drug. British Journal of Pharmacology (2000) 129, 95 - 100
authors.affiliation: AstraZeneca R&D Charnwood, Bakewell Road, Loughborough LE11 5RH, UK. richard.green@astrazeneca.com
authors.forename: A R
authors.initials: AR
authors.lastname: Green
authors.forename: T K
authors.initials: TK
authors.lastname: Murray
authors.forename: A
authors.initials: A
authors.lastname: Misra
authors.forename: M F
authors.initials: MF
authors.lastname: Snape
authors.forename: J A
authors.initials: JA
authors.lastname: Jones
authors.forename: A J
authors.initials: AJ
authors.lastname: Cross
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002545:Brain Ischemia / Q000188:drug therapy / Q000473:pathology; D002719:Chlormethiazole / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology*; D005849:Gerbillinae; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009410:Nerve Degeneration / Q000473:pathology / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology*; D013844:Thiazoles / Q000097:blood / Q000378:metabolism
chemical_list: D006993:Hypnotics and Sedatives; C406476:NLA 715; D018696:Neuroprotective Agents; D013844:Thiazoles; D002719:Chlormethiazole; C025062:5-acetyl-4-methylthiazole; C025061:5-(1-hydroxyethyl)-4-methylthiazole